Why Regeneron Pharmaceuticals, Inc. (REGN) stock moved
Regeneron Pharmaceuticals, Inc. (REGN) shares rose 0.9% to $746.54 as of October 9, 2026, a slight gain from the prior close of $739.57. BestStocks flagged the session as a major change for REGN. Below, we break down what changed for REGN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
REGN climbed 0.9% to $746.54
REGN rose 0.9% in its latest session, moving from $739.57 to $746.54.
What it means for Regeneron Pharmaceuticals, Inc. investors
For Regeneron Pharmaceuticals, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.9% session move; Positive price momentum. Weighing against that: Regeneron and Sanofi announced an expansion of their alliance valued at up to $8 billion to develop next-generation, long-acting immunology antibodies alongside their existing DUPIXENT collaboration, according to Globe Newswire and the Wall Street Journal; Regeneron Pharmaceuticals, Inc. moved -3.37% intraday from $788.04 to $761.46. Wall Street's consensus price target sits at $849.84, implying +13.8% upside from $746.54. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality weak (34/100). With earnings roughly 21 days out, the next report is the most likely near-term test of the move.
REGN price reaction
REGN last traded at $746.54, up $6.97 (+0.94%) from the previous close of $739.57. The session traded on 0.6× average volume (below avg), so participation was unremarkable.
Bullish and bearish analyst opinions on Regeneron Pharmaceuticals, Inc. (REGN)
The consensus analyst price target on Regeneron Pharmaceuticals, Inc. (REGN) is $849.84, 13.8% above the recent $746.54. Over the past 90 days analysts logged 1 upgrade, 16 maintains, and 0 downgrades. Here is how the bullish and bearish cases on REGN line up.
The bullish case
- Wall Street's consensus price target of $849.84 implies +13.8% upside from $746.54.
- The Street's most bullish target is $1,030.00 (+38.0%).
- 1 analyst upgrade in the past 90 days, most recently Argus Research to Buy (2026-10-01).
- Positive 0.9% session move.
- Positive price momentum.
The bearish case
- Regeneron and Sanofi announced an expansion of their alliance valued at up to $8 billion to develop next-generation, long-acting immunology antibodies alongside their existing DUPIXENT collaboration, according to Globe Newswire and the Wall Street Journal.
- Regeneron Pharmaceuticals, Inc. moved -3.37% intraday from $788.04 to $761.46.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 9, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for REGN
Frequently asked questions about REGN
Why did Regeneron Pharmaceuticals, Inc. (REGN) stock move?
REGN rose 0.9% to $746.54. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did REGN stock rise?
REGN gained 0.94% ($6.97) versus the prior close of $739.57, last trading at $746.54 on 0.6× average volume.
When is Regeneron Pharmaceuticals, Inc.'s next earnings date?
REGN's next earnings report is estimated for 2026-10-30 — about 21 days away.
What is the analyst price target for REGN?
The consensus analyst price target for REGN is $849.84, about 13.8% above the current $746.54. Over the past 90 days, analysts recorded 1 upgrade, 16 maintains, and 0 downgrades.
How BestStocks tracks REGN
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared REGN-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for REGN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 9, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.